Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Combined in silico, ex vivo, and in vivo Assessment of L-17, a Thiadiazine Derivative With Putative Neuroprotective and Antidepressant-Like Effects

Version 1 : Received: 25 October 2021 / Approved: 26 October 2021 / Online: 26 October 2021 (12:32:43 CEST)

How to cite: Sarapultsev, A.; Vassiliev, P.; Grinchii, D.; Kiss, A.; Mach, M.; Osacká, J.; Balloova, A.; Paliokha, R.; Kochetkov, A.N.; Sidorova, L.; Sarapultsev, P.; Chupakhin, O.; Rantsev, M.; Vassiliev, P.; Dremencov, E. Combined in silico, ex vivo, and in vivo Assessment of L-17, a Thiadiazine Derivative With Putative Neuroprotective and Antidepressant-Like Effects. Preprints 2021, 2021100384 (doi: 10.20944/preprints202110.0384.v1). Sarapultsev, A.; Vassiliev, P.; Grinchii, D.; Kiss, A.; Mach, M.; Osacká, J.; Balloova, A.; Paliokha, R.; Kochetkov, A.N.; Sidorova, L.; Sarapultsev, P.; Chupakhin, O.; Rantsev, M.; Vassiliev, P.; Dremencov, E. Combined in silico, ex vivo, and in vivo Assessment of L-17, a Thiadiazine Derivative With Putative Neuroprotective and Antidepressant-Like Effects. Preprints 2021, 2021100384 (doi: 10.20944/preprints202110.0384.v1).

Abstract

L-17 is a thiadiazine derivative with putative anti-inflammatory, neuroprotective, and antidepressant-like properties. In this study, we applied combined in silico, ex vivo, and in vivo electrophysiology techniques to reveal the potential mechanism of action of L-17. PASS 10.4 Professional Extended software suggested that L-17 might have pro-cognitive, antidepressant, and antipsychotic effects. Docking energy assessment with AutoDockVina predicted that the binding affinities of L-17 to the serotonin transporter (SERT) and serotonin receptors 3 and 1A (5-HT3 and 5-HT1A) receptors are compatible to the selective serotonin reuptake inhibitor (SSRI) fluoxetine and selective antagonists of 5-HT3 and 5-HT1A receptors, granisetron and WAY100135, respectively. Acute pre-treatment with L-17 robustly increased c-Fos immunoreactivity in the amygdala (central nucleus), suggesting increased neuronal excitability in this brain area after L-17 administration. Acute L-17 also dose-dependently inhibited of 5-HT neurons of the dorsal raphe nucleus (DRN). This inhibition was partially reversed by subsequent administration of WAY100135, suggesting the involvement of extracellular 5-HT. Based on in silico predictions, c-Fos immunohistochemistry, and in vivo electrophysiology, we suggest that L-17 is a potent 5-HT reuptake inhibitor and/or partial 5-HT1A receptor antagonist. Thus, L-17 might be a representative of a new class of antidepressant drugs. Since L-17 also possesses neuro- and cardio-protective properties, it can be useful in post-stroke and post-myocardial infarction (MI) depression. In general, combined in silico predictions and ex vivo neurochemical and in vivo electrophysiological assessment might be a useful strategy for early preclinical assessment of the affectivity and neural mechanism in action of the novel CNS drugs.

Keywords

thiadizines; serotonin transporter (SERT); serotonin-1A receptor; serotonin-3 receptor; docking; docking energy; binding affinity; binding mechanism; c-Fos; immunohistochemistry; electrophysiology

Subject

MEDICINE & PHARMACOLOGY, Psychiatry & Mental Health studies

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.